Drug intelligence / Profile preview

meropenem + minocycline

Development stage: Preclinical
Lead developer: Sumitomo Pharma
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

A combination antibiotic therapy consisting of meropenem (a carbapenem antibiotic) and minocycline (a tetracycline antibiotic). This combination has been studied for its potential synergistic effects against multidrug-resistant bacterial infections, particularly those caused by Acinetobacter baumannii. Meropenem works by interfering with bacterial cell wall synthesis, while minocycline inhibits bacterial protein synthesis. The combination may provide enhanced antimicrobial activity against resistant pathogens compared to either drug alone.

Targets

PBP (Penicillin-binding protein family)Bacterial Ribosome

Beyond the preview

Go deeper on meropenem + minocycline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on meropenem + minocycline.

Explore the full profile